S C Grant|L E Magee - JoVE Visualize

Showing results (41-50 of 59) with videos related to

Pageof 6

Sort By:

Neuroscience|September 17, 2005

A three-dimensional digital atlas database of the adult C57BL/6J mouse brain by magnetic resonance microscopyY Ma, P R Hof, S C Grant, et al.

Transplantation|November 27, 1995

A genetic marker of high TNF-alpha production in heart transplant recipientsD M Turner, S C Grant, W R Lamb, et al.

Molecular Ecology|April 8, 2006

Biogeographic history of an Australian freshwater shrimp, Paratya australiensis (Atyidae): the role life history transition in phylogeographic diversificationB D Cook, A M Baker, T J Page, et al.

American Journal of Clinical Oncology|August 1, 1995

Ifosfamide plus high-dose cisplatin in patients with non-small cell lung cancer previously treated with chemotherapyV A Miller, J R Rigas, K M Pisters, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 13, 1998

Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancerV A Miller, K K Ng, S C Grant, et al.

European Journal of Nuclear Medicine|February 1, 1996

Targeting of small-cell lung cancer using the anti-GD2 ganglioside monoclonal antibody 3F8: a pilot trialS C Grant, L Kostakoglu, M G Kris, et al.

Neuromolecular Medicine|October 5, 2007

Magnetic resonance microscopy and immunohistochemistry of the CNS of the mutant SOD murine model of ALS reveals widespread neural deficitsM S Petrik, J M B Wilson, S C Grant, et al.

Cancer Chemotherapy and Pharmacology|January 1, 1997

Phase II trial of chloroquinoxaline sulfonamide (CQS) in patients with stage III and IV non-small-cell lung cancerV A Miller, J R Rigas, W P Tong, et al.

American Journal of Clinical Oncology|October 22, 1998

Phase II trial of topotecan administered as a 21-day continuous infusion in previously untreated patients with stage IIIB and IV non-small-cell lung cancerH L Kindler, M G Kris, I E Smith, et al.

Cancer|February 15, 1995

Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancerV A Miller, J R Rigas, P A Francis, et al.

Pageof 6

Showing results (41-50 of 59) with videos related to

Sort By:

Pageof 6

Neuroscience|September 17, 2005

A three-dimensional digital atlas database of the adult C57BL/6J mouse brain by magnetic resonance microscopyY Ma, P R Hof, S C Grant, et al.

Transplantation|November 27, 1995

A genetic marker of high TNF-alpha production in heart transplant recipientsD M Turner, S C Grant, W R Lamb, et al.

Molecular Ecology|April 8, 2006

Biogeographic history of an Australian freshwater shrimp, Paratya australiensis (Atyidae): the role life history transition in phylogeographic diversificationB D Cook, A M Baker, T J Page, et al.

American Journal of Clinical Oncology|August 1, 1995

Ifosfamide plus high-dose cisplatin in patients with non-small cell lung cancer previously treated with chemotherapyV A Miller, J R Rigas, K M Pisters, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 13, 1998

Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancerV A Miller, K K Ng, S C Grant, et al.

European Journal of Nuclear Medicine|February 1, 1996

Targeting of small-cell lung cancer using the anti-GD2 ganglioside monoclonal antibody 3F8: a pilot trialS C Grant, L Kostakoglu, M G Kris, et al.

Neuromolecular Medicine|October 5, 2007

Magnetic resonance microscopy and immunohistochemistry of the CNS of the mutant SOD murine model of ALS reveals widespread neural deficitsM S Petrik, J M B Wilson, S C Grant, et al.

Cancer Chemotherapy and Pharmacology|January 1, 1997

Phase II trial of chloroquinoxaline sulfonamide (CQS) in patients with stage III and IV non-small-cell lung cancerV A Miller, J R Rigas, W P Tong, et al.

American Journal of Clinical Oncology|October 22, 1998

Phase II trial of topotecan administered as a 21-day continuous infusion in previously untreated patients with stage IIIB and IV non-small-cell lung cancerH L Kindler, M G Kris, I E Smith, et al.

Cancer|February 15, 1995

Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancerV A Miller, J R Rigas, P A Francis, et al.

Pageof 6